Pfizer completes acquisition of Array Biopharma
This article was originally published here
As Array becomes part of Pfizer, it brings an impressive existing portfolio that includes the approved combined use of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) for the treatment of
The post Pfizer completes acquisition of Array Biopharma appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!